Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Pimasertib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck KGaA; Merck Serono
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.